148 related articles for article (PubMed ID: 21463143)
1. Drug development for metastatic castration-resistant prostate cancer: current status and future perspectives.
Lassi K; Dawson NA
Future Oncol; 2011 Apr; 7(4):551-8. PubMed ID: 21463143
[TBL] [Abstract][Full Text] [Related]
2. Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer.
Armstrong AJ; George DJ
Prostate Cancer Prostatic Dis; 2010 Jun; 13(2):108-16. PubMed ID: 20066005
[TBL] [Abstract][Full Text] [Related]
3. Emerging and second line therapies for the management of metastatic castration-resistant prostate cancer: the Australian perspective.
Parente P; Parnis F; Gurney H
Asia Pac J Clin Oncol; 2012 Mar; 8(1):31-42. PubMed ID: 22369442
[TBL] [Abstract][Full Text] [Related]
4. Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer.
Armstrong AJ; Garrett-Mayer E; de Wit R; Tannock I; Eisenberger M
Clin Cancer Res; 2010 Jan; 16(1):203-11. PubMed ID: 20008841
[TBL] [Abstract][Full Text] [Related]
5. Update on castrate-resistant prostate cancer: 2010.
Lassi K; Dawson NA
Curr Opin Oncol; 2010 May; 22(3):263-7. PubMed ID: 20177381
[TBL] [Abstract][Full Text] [Related]
6. [Castration-resistant prostate cancer: where are we going?].
Alcaraz A; Medina R; Maroto P; Climent MÁ; Castellano D; Carles J
Actas Urol Esp; 2012 Jun; 36(6):367-74. PubMed ID: 22188754
[TBL] [Abstract][Full Text] [Related]
7. Management of metastatic castration-resistant prostate cancer after first-line docetaxel.
Harrington JA; Jones RJ
Eur J Cancer; 2011 Sep; 47(14):2133-42. PubMed ID: 21658937
[TBL] [Abstract][Full Text] [Related]
8. Treatment decisions for metastatic castration-resistant prostate cancer progressing after docetaxel chemotherapy: the role of cabazitaxel in the continuum of care.
Heidenreich A; Pfister D
Eur Urol; 2012 Dec; 62(6):1201-4. PubMed ID: 22964168
[No Abstract] [Full Text] [Related]
9. Is there a role for chemotherapy in nonmetastatic prostate cancer?
Keizman D; Eisenberger M
Curr Opin Support Palliat Care; 2010 Sep; 4(3):141-6. PubMed ID: 20613534
[TBL] [Abstract][Full Text] [Related]
10. Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancer.
Beardsley EK; Chi KN
Curr Opin Support Palliat Care; 2008 Sep; 2(3):161-6. PubMed ID: 18685415
[TBL] [Abstract][Full Text] [Related]
11. [Prostate cancer and chemotherapy: standards care and perspectives].
Hadjarab Y; Oudard S
Bull Cancer; 2012 Jul; 99 Suppl 1():S46-56. PubMed ID: 22516516
[TBL] [Abstract][Full Text] [Related]
12. Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium.
Harzstark AL; Rosenberg JE; Weinberg VK; Sharib J; Ryan CJ; Smith DC; Pagliaro LC; Beer TM; Liu G; Small EJ
Cancer; 2011 Jun; 117(11):2419-25. PubMed ID: 24048789
[TBL] [Abstract][Full Text] [Related]
13. Current second-line treatment options for patients with castration resistant prostate cancer (CRPC) resistant to docetaxel.
Arsov C; Winter C; Rabenalt R; Albers P
Urol Oncol; 2012; 30(6):762-71. PubMed ID: 20884252
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy-based treatment for castration-resistant prostate cancer.
Seruga B; Tannock IF
J Clin Oncol; 2011 Sep; 29(27):3686-94. PubMed ID: 21844499
[TBL] [Abstract][Full Text] [Related]
15. Current and emerging treatment modalities for metastatic castration-resistant prostate cancer.
Bracarda S; Logothetis C; Sternberg CN; Oudard S
BJU Int; 2011 Apr; 107 Suppl 2():13-20. PubMed ID: 21382150
[TBL] [Abstract][Full Text] [Related]
16. TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer.
Oudard S
Future Oncol; 2011 Apr; 7(4):497-506. PubMed ID: 21463139
[TBL] [Abstract][Full Text] [Related]
17. Advances in the treatment of metastatic prostate cancer.
Chowdhury S; Kirby R
Practitioner; 2013 Apr; 257(1760):15-8, 2. PubMed ID: 23724747
[TBL] [Abstract][Full Text] [Related]
18. Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer.
Miyake H; Sakai I; Terakawa T; Harada K; Fujisawa M
Urol Oncol; 2013 Aug; 31(6):733-8. PubMed ID: 21782481
[TBL] [Abstract][Full Text] [Related]
19. The role of abiraterone in the management of metastatic castration-resistant prostate cancer.
Rawlinson A; Mohammed A; Beatty J; Bell R; Miller M
Expert Rev Anticancer Ther; 2012 Apr; 12(4):429-37. PubMed ID: 22500680
[TBL] [Abstract][Full Text] [Related]
20. Castration-resistant prostate cancer: AUA Guideline.
Cookson MS; Roth BJ; Dahm P; Engstrom C; Freedland SJ; Hussain M; Lin DW; Lowrance WT; Murad MH; Oh WK; Penson DF; Kibel AS
J Urol; 2013 Aug; 190(2):429-38. PubMed ID: 23665272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
